cisplatin micelle injection (HA132) / CSPC Pharma - LARVOL DELTA

The Effect of Probiotics on Health in Pregnancy and Infants: A Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, Nutrients) - " At 28 weeks of gestation, 180 healthy pregnant women were randomized to receive either a placebo (n = 90) or a probiotic supplement (n = 90), Prenatis™, containing 5 billion CFU/day of Lacticaseibacillus rhamnosus Rosell®-11 and Bifidobacterium bifidum HA-132...Probiotics promoted the vertical transmission of beneficial species and the induction of a highly interconnected microbiota, structured around key species. Probiotic supplementation during the third trimester of pregnancy and lactation is a valid strategy for conferring benefits to mothers and infants."

Clinical • Journal • Infectious Disease

THE IMPACT OF GUT MICROBIOTA MODULATION ON THE EVOLUTION OF CELIAC DISEASE (UEGW 2024) - "Aims & We designed a study to determine the potential effect of a combination of Lactobacillus (acidophilus HA-122, casei HA-108) and Bifidobacterium bifidum HA-132 on perception of symptoms and on the inflammatory-immunological markers in patients with active CD.25 adult patients were randomized to receive bid of a probiotic combination of Lactobacilus and Biffidobacter for six weeks (13 pts) va a placebo group (12 pts) while being on gluten-free diet... Tests and the lymphocyte infiltrates in the mucosal biopsy specimen in uur study suggests that prebiotic/probiotic treatment may improve symptoms and serology in celiac disease."

Gut Microbiota • Celiac Disease • Constipation • Dyspepsia • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Pain • IL1B • IL6 • TNFA

METABOLOMICS-DRIVEN ASSESSMENT OF SYMBIOTIC ASSOCIATIONS WITH HMOS (ESPGHAN 2024) - "Metabolomics augments microbiome metabolic translation towards benefit areas such as immunity, gut health, inflammation and cognition, with symbiotic association with HMOs."

Inflammation • Inflammatory Bowel Disease

Enteral supplementation with probiotics in preterm infants: A retrospective cohort study and 6-year follow-up. (PubMed, Front Nutr) - "In October 2014, our NICU introduced an enteral probiotics supplementation protocol for infants born <33 weeks GA or BW <1,500 g. Infants received 0.5 g of Bifidobacterium breve HA-129, Lacticaseibacillus rhamnosus HA-111, Bifidobacterium bifidum HA-132, Bifidobacterium longum subsp...Data from the Canadian Neonatal Network not only showed a consistently high rate of NEC in October 2014, but also identified exceedingly high rates (8.7-15.6%) in some hospitals up to 2021, while our rates have been consistently low with using the probiotic as standard therapy for low BW premature babies, with no serious side effects reported. In conclusion, the introduction of a five-strain probiotic natural health product has coincided with a reduced incidence and complications of NEC in our NICU setting."

Journal • Retrospective data • Critical care • Gastrointestinal Disorder • Small for Gestational Age

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1/2 | N=126 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

New P1/2 trial • Gastrointestinal Cancer • Oncology • Solid Tumor